Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
2 June 2024
| 03:28 | WINREVAIR diffhist +581 Kosar Doraghi talk contribs | ||||
|
|
02:54 | (Upload log) [Kosar Doraghi (9×)] | |||
|
|
02:54 Kosar Doraghi talk contribs uploaded File:IMG 1235.jpeg | ||||
|
|
02:53 Kosar Doraghi talk contribs uploaded File:IMG 1234.jpeg | ||||
|
|
02:52 Kosar Doraghi talk contribs uploaded File:IMG 1231.jpeg | ||||
|
|
02:51 Kosar Doraghi talk contribs uploaded File:IMG 1232.jpeg | ||||
|
|
02:49 Kosar Doraghi talk contribs uploaded File:IMG 1230.jpeg | ||||
|
|
02:49 Kosar Doraghi talk contribs uploaded File:IMG 1227.jpeg | ||||
|
|
02:48 Kosar Doraghi talk contribs uploaded File:IMG 1236.jpeg | ||||
|
|
02:46 Kosar Doraghi talk contribs uploaded File:IMG 1237.jpeg | ||||
|
|
02:41 Kosar Doraghi talk contribs uploaded File:IMG 1226.jpeg | ||||
1 June 2024
| 03:21 | Template:KDRG diffhist +15 Kosar Doraghi talk contribs | ||||
| N 03:20 | WINREVAIR diffhist +16,566 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=sotatercept-csrk |aOrAn=an |drugClass=activin signaling inhibitor |indicationType=treatment |indication=adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events |hasBlackBoxWarning=Yes |adverseReactions=headache, epistaxis, rash, telangiect...") | ||||
31 May 2024
|
|
m 23:35 | Non-degenerate nucleotides per response element 2 changes history +1 [Marshallsumter (2×)] | |||
| m |
|
23:35 (cur | prev) 0 Marshallsumter talk contribs (→Averages per Orders) | |||
| m |
|
23:18 (cur | prev) +1 Marshallsumter talk contribs (→Averages per Orders) | |||
30 May 2024
|
|
m 23:53 | Non-degenerate nucleotides per response element 2 changes history −52 [Marshallsumter (2×)] | |||
| m |
|
23:53 (cur | prev) +2 Marshallsumter talk contribs (→Averages per Orders) | |||
| m |
|
06:03 (cur | prev) −54 Marshallsumter talk contribs (→Tabulation of counts) | |||
28 May 2024
| m 07:35 | Non-degenerate nucleotides per response element diffhist 0 Marshallsumter talk contribs (→Tabulation of counts) | ||||
27 May 2024
|
|
N 23:47 | Template:JR 2 changes history +44 [Jonathan Reyes (2×)] | |||
|
|
23:47 (cur | prev) −25 Jonathan Reyes talk contribs | ||||
| N |
|
22:59 (cur | prev) +69 Jonathan Reyes talk contribs (Created page with "Jonathan Reyes, M.D.[jona3098reyes@gmail.com]") | |||
| N 23:42 | Evinacumab-dgnb diffhist +627 Jonathan Reyes talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{JR}} |genericName=evinacumab-dgnb |aOrAn=an |drugClass=angiopoietin-like 3 (ANGPTL3) inhibitor |indicationType=treatment |indication=Evanicumab-dgnb is an angiopoietin-like 3 (ANGPTL3) inhibitor that is FDA approved for the treatment of an adjunct to other low-density lipoproteincholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholestero...") | ||||
26 May 2024
| m 20:05 | Non-degenerate nucleotides per response element diffhist −50 Marshallsumter talk contribs (→Tabulation of counts) | ||||
25 May 2024
| m 19:41 | Non-degenerate nucleotides per response element diffhist 0 Marshallsumter talk contribs (→Averages per Orders) | ||||
24 May 2024
|
|
m 21:07 | Non-degenerate nucleotides per response element 2 changes history −52 [Marshallsumter (2×)] | |||
| m |
|
21:07 (cur | prev) −52 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
16:55 (cur | prev) 0 Marshallsumter talk contribs (→Averages per Orders) | |||
23 May 2024
|
|
N 14:51 | Glofitamab-gxbm 2 changes history +8,803 [Muhammad Waleed (2×)] | |||
|
|
14:51 (cur | prev) +6,189 Muhammad Waleed talk contribs | ||||
| N |
|
14:40 (cur | prev) +2,614 Muhammad Waleed talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=glofitamab. |aOrAn=a |drugClass=bispecific antibodies |indicationType=treatment |indication=COLUMVI (glofitamab) has been approved by the FDA for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or large B-cell lymphoma arising from follicular lymphoma aft...") | |||
|
|
N 14:22 | Rozanolixizumab-noli 2 changes history +8,759 [Muhammad Waleed (2×)] | |||
|
|
14:22 (cur | prev) +5,524 Muhammad Waleed talk contribs | ||||
| N |
|
12:43 (cur | prev) +3,235 Muhammad Waleed talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Rozanolixizumab-noli (Rystiggo) |aOrAn=a |drugClass=Neonatal Fc receptor blocker |indicationType=treatment |indication=Rystiggo is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. |adverseReac...") | |||
|
|
m 07:03 | Non-degenerate nucleotides per response element 2 changes history −98 [Marshallsumter (2×)] | |||
| m |
|
07:03 (cur | prev) −49 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:01 (cur | prev) −49 Marshallsumter talk contribs (→Tabulation of counts) | |||
|
|
04:38 | Pegunigalsidase alfa-iwxj 4 changes history +3,608 [Alen Antony (4×)] | |||
|
|
04:38 (cur | prev) +1,255 Alen Antony talk contribs | ||||
|
|
02:34 (cur | prev) +83 Alen Antony talk contribs | ||||
|
|
02:32 (cur | prev) +931 Alen Antony talk contribs | ||||
|
|
02:18 (cur | prev) +1,339 Alen Antony talk contribs | ||||
|
|
02:01 | Template:KDRG 2 changes history +15 [Kosar Doraghi (2×)] | |||
|
|
02:01 (cur | prev) +18 Kosar Doraghi talk contribs | ||||
|
|
02:00 (cur | prev) −3 Kosar Doraghi talk contribs | ||||
| N 02:00 | Aprocitentan diffhist +16,419 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar.Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=aprocitentan |aOrAn=an |drugClass=endothelin receptor antagonist |indicationType=treatment |indication=hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs |hasBlackBoxWarning=Yes |adverseReactions=edema/fluid retention and anemia |blackBoxWarningTitle=W...") | ||||
|
|
01:49 | (Upload log) [Kosar Doraghi (3×)] | |||
|
|
01:49 Kosar Doraghi talk contribs uploaded File:IMG 1225.jpeg | ||||
|
|
01:28 Kosar Doraghi talk contribs uploaded File:IMG 1224.jpeg | ||||
|
|
01:28 Kosar Doraghi talk contribs uploaded File:IMG 1223.jpeg | ||||
| 00:06 | Sandbox diffhist +9 Alberto Castro Molina talk contribs | ||||
22 May 2024
| 23:54 | Sandbox diffhist −30,274 Alberto Castro Molina talk contribs (Replaced content with " File:Captura de Pantalla 2024-05-18 a la(s) 9.33.11 p.m..png") | ||||
_9.33.11_p.m..png){kind=link}
| 23:53 | Upload log Alberto Castro Molina talk contribs uploaded File:Captura de Pantalla 2024-05-18 a la(s) 9.33.11 p.m..png | ||||
|
|
m 21:33 | Non-degenerate nucleotides per response element 2 changes history +1 [Marshallsumter (2×)] | |||
| m |
|
21:33 (cur | prev) 0 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
04:17 (cur | prev) +1 Marshallsumter talk contribs (→Averages per Orders) | |||
|
|
04:26 | Pegunigalsidase alfa-iwxj 3 changes history +1,266 [Alen Antony (3×)] | |||
|
|
04:26 (cur | prev) +459 Alen Antony talk contribs | ||||
|
|
04:06 (cur | prev) +752 Alen Antony talk contribs | ||||
|
|
03:57 (cur | prev) +55 Alen Antony talk contribs | ||||
| 04:02 | FUTIBATINIB diffhist +3,715 Hafiza Amna Qadeer talk contribs | ||||